Habibullah Eatamadi | Thyroid eye disease | Best Researcher Award

Dr. Habibullah Eatamadi | Thyroid eye disease | Best Researcher Award

Consultant Oculoplastic Surgeon, Sheikh Shakhbout Medical City, United Arab Emirates

Dr. Habibullah Eatamadi is a distinguished Consultant Oculoplastics, Lacrimal, and Orbital Surgeon with extensive experience in both clinical practice and academic leadership. Born on February 3, 1968, he holds Irish nationality and is registered with multiple medical councils, including the UAE DOH and the UK GMC. He has served in leading ophthalmic institutions across the UK and UAE, such as Sheikh Shakhbout Medical City and Sheikh Khalifa Medical City. His fellowships in Oculoplastics and Pediatric Ophthalmology from top UK hospitals have shaped his expertise in complex surgeries. He is a member of prestigious societies like ASOPRS, BOPSS, and the AAO. Known for his compassionate care and dedication to innovation, Dr. Eatamadi is actively involved in teaching, clinical audits, and presenting at global conferences. His leadership in ophthalmology has had a transformative impact on eye care services in the UAE.

Profile

🎓 Education

Dr. Eatamadi completed his MD from Albert Szent Gyorgyi Medical University, Szeged, Hungary, in 1993. His postgraduate education includes a specialty degree in Ophthalmology from Haynal Imre Postgraduate Medical University, Budapest, in 1997, followed by the FRCS in Ophthalmology from the Royal College of Surgeons, Edinburgh, in 1999. To complement his clinical expertise with administrative acumen, he pursued a Master’s degree in Healthcare Management from Zayed University in collaboration with North Carolina University in 2014. His education reflects a well-rounded foundation in both medical science and healthcare leadership. He holds full registrations with the Irish Medical Council (IMC), UK General Medical Council (GMC), and the UAE Department of Health. Dr. Eatamadi’s continuous pursuit of knowledge through fellowships and academic programs has been pivotal in shaping his subspecialty focus on Oculoplastics, Lacrimal, and Orbital Surgery. His academic background demonstrates both depth and breadth in clinical medicine and healthcare systems.

đź§Ş Experience

Dr. Habibullah Eatamadi has over two decades of international clinical experience in ophthalmology, particularly in Oculoplastics, Lacrimal, and Orbital Surgery. He currently serves as Consultant Ophthalmic Surgeon at Sheikh Shakhbout Medical City, UAE, since December 2020. Previously, he was Head of the Department at Sheikh Khalifa Medical City (2011–2020) and Consultant at Tawam Hospital (2008–2011). His fellowship training across top UK hospitals, including the Western Eye Hospital and University Hospital Nottingham, has provided a strong foundation in subspecialties like pediatric ophthalmology, endolacrimal, and orbital surgery. He has also worked at Leicester Royal Teaching Hospital as a locum ophthalmologist. In addition to clinical duties, Dr. Eatamadi was the Ophthalmology Residency Program Director (2011–2016) and continues to serve as Associate Program Director. His teaching, audit, and surgical experience have made him a key contributor to the evolution of ophthalmic practice in the UAE and beyond.

🏅 Awards and Honors

Dr. Eatamadi has been recognized for his surgical outcomes, academic leadership, and commitment to excellence in ophthalmology. His internal audits, including the conjunctival ptosis surgery audit at SKMC (2017–2020), achieved a 92% success rate with minimal complications and was subsequently published, reflecting his commitment to clinical quality and evidence-based care. Another notable achievement was his audit on external DCR at Tawam Hospital (2009–2010), where he demonstrated a 95% success rate, aligning with global standards. He is regularly invited to present at international conferences such as the British Oculoplastic Surgery Society and the Emirates Thyroid Congress, where his recent work on thyroid eye disease and biologic treatments has gained regional recognition. As an active member of professional societies including ASOPRS and ITEDS, he contributes to knowledge dissemination and practice improvement. His honors stem from years of clinical excellence, educational mentorship, and innovation in oculoplastic and orbital surgery.

🔬 Research Focus

Dr. Eatamadi’s research interests focus on clinical outcomes and therapeutic advancements in oculoplastics, lacrimal, and orbital surgery. His work integrates surgical precision with modern therapeutic approaches, such as the use of biologics in thyroid eye disease, including Tocilizumab and Teprotumumab, which he presented at leading conferences in 2025. His research extends to outcome-based audits, such as his evaluation of DCR procedures and conjunctival ptosis repairs, reflecting his evidence-based approach to patient care. Additionally, his academic involvement includes curriculum development for ophthalmology residents, promoting research-driven education. Through case audits, clinical trials, and presentations, Dr. Eatamadi continues to shape the future of subspecialty ophthalmology in the UAE. He is particularly interested in enhancing surgical outcomes, reducing complications, and applying new biologics for complex orbital inflammatory conditions. His research focus supports his dual role as a clinician and educator, ensuring that scientific advances are translated into high-quality patient outcomes.

âś… Conclusion

Dr. Habibullah Eatamadi is a highly accomplished oculoplastic surgeon whose international training, extensive experience, academic contributions, and research innovations have significantly advanced ophthalmic care in the UAE and beyond.

Publications
  • Tocilizumab use for optic nerve compression in thyroid eye disease: a prospective longitudinal cohort

  • Eatamadi, H., AlMazrouiel, O., Al Qatan, N., Ibrahim, H., & Eatamadi, S. (2025). Teprotumumab use in Thyroid Eye Disease: Clinical Outcomes in the United Arab Emirates – A First Regional Case Series. Seminars in Ophthalmology. https://doi.org/10.1080/08820538.2025.2503911
  • Habroosh, F. A., Albrashdi, S. S., Alsaadi, A. H., Eatamadi, H. (2024). Tocilizumab Use for Optic Nerve Compression in Thyroid Eye Disease: A Prospective Longitudinal Cohort. International Ophthalmology, 44, 222. https://doi.org/10.1007/s10792-024-03143-4
  • Eatamadi, H., et al. (2024). Economic Burden Impact of Thyroid Eye Disease in the United Arab Emirates. Poster presented at ISPOR USA, May 2024, Atlanta, GA, USA.
  • Alalawi, F., Almazroui, O., Alsaadi, A., Eatamadi, H. (2023). Severe Dysthyroid Optic Neuropathy Following SARS-CoV-2 Vaccination Treated with Tocilizumab: First Two Reported Cases. Open Journal of Clinical & Medical Case Reports, 9(19).
  • Almazrouei, O., Alalawi, F., Albrashdi, S., Alsharqi, H., Alsaadi, A., Hammad, M., Sabri, A., Eatamadi, H. (2023). A 46-Year-Old Woman with a 4-Year History of Graves’ Disease, with Severe Corticosteroid-Unresponsive Thyroid Eye Disease, Successfully Treated with Tocilizumab. American Journal of Case Reports, 24, e938487. https://doi.org/10.12659/AJCR.938487